The global axial spondyloarthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Axial spondyloarthritis is a type of inflammatory arthritis. It primarily affects the spine and the sacroiliac (SI) joints that are connected to the lower spine to the pelvis which results in pain in the lower back, hips, and buttocks. The major factor driving the growth of the market is the new product launches and drug approval across the globe.
For instance, in August 2019, Eli Lilly and Company announced the approval of Taltz (ixekizumab) injection 80 mg/mL from the US Food and Drug Administration (FDA). It is used for the treatment of active ankylosing spondylitis (AS) which is also known as radiographic axial spondyloarthritis (r-axSpA) in adults. Additionally, in June 2020, Novartis announced the approval of Cosentyx (secukinumab) from the US Food and Drug Administration (FDA). It is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).
To Request a Sample of our Report on Axial Spondyloarthritis Drugs Market: https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drugs-market
Some major players in the market include AbbVie Inc., Novartis International AG, and Johnson & Johnson, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, AbbVie announced the submission of applications to seek approvals for upadacitinib (RINVOQ, 15 mg) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Upadacitinib (RINVOQ, 15 mg) is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Market Coverage
- The market number available for – 2022-2028
- Base year- 2020
- Forecast period- 2022-2028
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- AbbVie Inc., Novartis International AG, and Johnson & Johnson Services, Inc., among others.
A full Report of Axial Spondyloarthritis Drugs Market is Available @ https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drugs-market
Global Axial Spondyloarthritis Drugs Market Report by Segment
By Type
- Certolizumab Pegol
- Etanercept Biosimilar
- Ixekizumab
- Secukinumab
- Others
By Application
- Clinic
- Hospital
- Homecare
Global Axial Spondyloarthritis Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
